Mark Steven Cohen

Medicine & Life Sciences

1. Withanolides 100%
2. withaferin A 86%
3. Adrenocortical Carcinoma 57%
4. Melanoma 53%
5. Cisplatin 48%
6. Neoplasms 45%
7. Squamous Cell Carcinoma of Head and Neck 44%
8. Physalis 41%
9. HSP90 Heat-Shock Proteins 37%
10. Thyroid Neoplasms 35%
11. Hyaluronic Acid 34%
12. Parathyroidectomy 33%
13. Apoptosis 32%
14. Medullary Thyroid cancer 32%
15. Primary Hyperparathyroidism 31%
16. Nanoconjugates 29%
17. Therapeutics 28%
18. Breast Neoplasms 27%
19. Entrepreneurship 26%
20. Neoplastic Stem Cells 25%
21. Inhibitory Concentration 50 24%
22. withalongolide A 4,19,27-triacetate 24%
23. Parathyroid Hormone 24%
24. 3-rhamnopyranosyl(1-4)-glucopyranosyl-12-diacetoxy-20-hydroxywitha-5,24-dienolide 24%
25. Drug Therapy 23%
26. Cell Line 22%
27. HDL Lipoproteins 21%
28. Survival 20%
29. Pharmaceutical Preparations 20%
30. Lymphatic System 19%
31. tanespimycin 17%
32. Cell Movement 16%
33. Lactones 16%
34. Novobiocin 16%
35. Neoplasm Metastasis 16%
36. In Vitro Techniques 15%
37. Heat-Shock Response 15%
38. Thyroidectomy 15%
39. Glioblastoma 15%
40. Down-Regulation 14%
41. Positron-Emission Tomography 14%
42. Surgeons 14%
43. Squamous Cell Neoplasms 14%
44. Nanoparticles 13%
45. Triple Negative Breast Neoplasms 13%
46. Growth 13%
47. Sentinel Lymph Node Biopsy 12%
48. Thyroid Nodule 12%
49. Deferoxamine 12%
50. KU135 12%